INDEX

Accelerated stability testing, 691–693
Accuracy, 730
Active pharmaceutical ingredients, 546–547, 563
Additives, 468–473, 467
Aluminum, 486, 489–491
Analytical method validation characteristics, 729–737
Anharmonicity, 372–373
Arrhenius equation, 691–693
Audit checklist, 225–237
Audit trail, 30
Biotechnological products, 668–671
Biowavers, 84–85
Box plot, 291
Bracketing, 592–594
Bulk pharmaceutical excipients, 547–548
Cause-and-effect diagram, 288
cGMP, 202–204
Change control, 89–91
Changes in manufacturing sites, 73–74
Chemical reaction kinetics, 627–628
Chemometrics, 386–409, 416–419
Class I, 166
Class II, 166
Class III, 166
Cleaning validation, 835–836
Climatic zones and recommended storage conditions, 578
Clogenicity, 106–107
Common Technical Document (CTD), 333–334
Competency-based training, 438–439
Components of validation activity, 93
Consent decrees, 59
Container extractables and leachables, 665–668
Containers, 481–483
Contaminants found in water for injection, 465
Control chart, 292–293
Control limits, 305–306
Corrective and Preventative Action (CAPA), 222, 25
Criminal proceedings, 61–66
Data mining, 358, 360–361
Data warehousing, 359
DEHP, 494, 509
Delivery systems, 506–516
Design of stability studies, 589–598
Detection limit, 733–734
Disgorgement, 59
Drug product salvaging, 24
Drug shelf life for multiple batches, 604–617

Elastomeric closures, 499–506
Electronic documents, 834–835
Endogenous contaminants, 459–479
Endotoxin and pyrogenicity testing, 106
Equipment system validation, 828–829
European pharmacopeia, 550–551
Excipients, 36–38, 562–563
Extractability tests, 506
Extractables, 667

Facilities validation, 818–822
Factor VII, 669–670
Factors influencing stability of drugs and drug products, 644–654
False Claims Act, 59–61
FDA inspections, 48–49
FDA’s Office of Criminal Investigations (OCI), 47
Finished products, 562
Form, 49–51, 483–484, 486–487
FT spectrometers, 414
Full stability study design, 591–592
Functional groups subject to oxidation, 694–695

Genetic stability, 109–112
Glass classification, 483
Glass containers, 656
GXP trainer(s), 444

Harmonization, 87–89
Hematopoiesis regulation, 108–109
Histogram, 289
Human platelet lysate, 101–102
Hygroscopicity, 652
Hyperspectral imaging, 412, 428–429

Immune modulatory effects, 108
Impurities in official articles, 458
Injunctions, 58–59
Instrument classification, 793
Internal audit, 217–220
International Conference on Harmonization, 133–135
Japanese pharmacopeia, 551
Leachables, 667
Lean manufacturing, 318–320

Legacy systems, 3–31
Limit of Detection (LOD), 767, 773–774
Limit of Quantification (LOQ), 774–775, 767
Limulus Amoeobocyte Lysate (LAL), 534
Linearity, 734–735, 775–776
Long-term stability analysis 598–626

Management trainer(s), 444
Manufacturing process validation, 822–825
Master production and control records, 21
Matrixing, 594–595
Measurement Uncertainty (MU), 751–752
Metals, 657
Microbial degredation, 697
Microbiological testing, 106
MIR/NIR chemical imaging, 381
Multiple Scatter Correction (MSC), 392
Multivariate image analysis, 418–419
National GMP regulations, 120–131
Natural tolerance limits, 305–306
New drug delivery systems, 671–673
Nonsterile liquid dosage forms, 661–662
Normal probability plot, 290–291

Object-oriented process modeling method (CIMp), 179
Operational classification, 801–802
Ordinary impurities, 458
Organoperoxide radicals, 667

Parental Drug Association (PDA), 504
Pareto Chart, 288–289
Particulate matter, 516–525
Patter recognition, 397–398
Pharmaceutical excipients, 653–654
Phenotypic identity of MSC, 106
Photolysis, 695
Photostability studies, 573–575
Polymerase Chain Reaction (PAR), 534
Polymeric materials, 495
Polymorphism, 652–653, 696
Potential tumorigenicity, 109–112
Precision, 730–731
Predicting shelf life, 690–691
Principle-component analysis, 393–395
Process capability indices, 306–307
Process controls, 355, 11–13
INDEX

Process Failure Risk Analysis (PFRA), 184
Process ownership, 264
Process validation, 91–92
Pyrogens, 11

Quality management, 241–252, 316–318
Quality risk management, 220–222, 333–335
Quantitation limit, 734
Quantum mechanical model, 369–372

Racemization, 696
Radio-Frequency Identification (RFID), 186–187
Raman spectroscopy, 376–379
Range, 735–736, 775–776
Real-Time Release (RTR), 341–342
Repeatability, 730
Reproducibility, 731
Residual solvents, 480–481
Returned drug products, 23–24
Risk-based orientation, 327–328
Root Mean Square Error of Prediction (RMSEP), 403
Root-cause analysis, 355
RSD (relative standard deviation), 34
Rubber, 657–658
Ruggedness, 769, 776

Safety trainer(s), 444
Scatter diagram, 289–290
Section 305 proceedings, 62
Seizures, 56–58
Sensitivity, 769, 776
Shelf life determination, 575–578
Short-term stability analysis, 626–633
SIMCA classification, 398–399
Site changes, 38–40

Software validation, 833–834
Solvents, 480–483
Solvolyis, 693–694
Sorption-desorption moisture transfer, 674–675
Special control charts, 302–306
Specification limits, 305–306
Specificity, 766
Stability and shelf life, 579–580, 585
Standard error of calibration (SEC), 404
Sterile liquid dosage forms, 662–665
Subject matter experts, 446
SUPAC, 68–72, 72–85, 85–86

Tandem mass spectrometry, 537
Traceability, 747–748
Training development, 449–451
Trend analysis, 217

U. S. Pharmacopeia (USP), 560, 548–550, 793, 688, 458
Validation master plan, 814–815
Validation plan, 794–796
Validation protocols, 815–818
Validation reports, 817–818
Validation, 30
Vaporization, 696–697
Variable-concentration kinetic experiments, 716–720
Variable-ionic-strength kinetic experiments, 720–721
Variable-temperature kinetic experiments, 713–716
Viability, 106
Vibrational spectroscopy, 365–386

Warning letter, 53–54
Water, 460
World Health Organization, 131